Low molecular weight heparin (LMWH) is an anticoagulant injected subcutaneously or intravenously and acts via activation of antithrombin III which in turn inactivates thrombin and factor Xa to produce ...

DVT affects 1-2 per 1000 adult population per annum in Western societies. It may be associated with pulmonary embolism, and some patients may develop postthrombotic syndrome with swelling of the leg, ...

Researchers suggest conclusive answers to key questions on the benefits of low molecular weight heparin (LMWH) for cancer patients remain elusive - despite promising results from large studies. For ...

Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months ...

Traditional treatment for proximal deep vein thrombosis (DVT) is to administer unfractionated heparin (UFH) for 5-7 days, followed by oral anticoagulant (warfarin) therapy. UFH requires ...

Please provide your email address to receive an email when new articles are posted on . For prevention of venous thromboembolism after noncardiac surgery, direct oral anticoagulants may be preferred ...

Patients with ST-segment elevation myocardial infarction (STEMI) benefit from treatment with aspirin and thrombolytic therapy; however, the conflicting findings of studies examining the effect of ...

Postoperative and preoperative start of low molecular weight heparin (LMWH) does not change the outcome of mortality or risk of reoperation in patients with hip fractures treated with osteosynthesis, ...

Protein S deficiency represents a rare but significant hereditary thrombophilia that poses substantial risks during pregnancy ...

The increased pregnancy rate at relatively advanced maternal age has led to higher rates of thromboembolic disease (TED), complicating pregnancy. A new paper discusses low-molecular-weight heparin ...